# The Dual Role of Conjugated Linoleic Acid in Obesity and Metabolic Disorders

## TL;DR

This review discusses how CLA can both help and hinder obesity and metabolic health, emphasizing the need for personalized approaches.

## Contribution

The paper highlights CLA's dual effects and advocates for personalized supplementation strategies based on individual factors.

## Key findings

- CLA promotes fat oxidation and modulates adipocyte function in preclinical studies.
- Human studies show inconsistent CLA effects due to dosage, isomer type, and individual variability.
- Personalized CLA supplementation could optimize benefits and reduce risks.

## Abstract

Conjugated Linoleic Acid (cis‐9, trans‐11, CLA)/(trans‐10, cis‐12, CLA) has been extensively studied for its role in obesity control and metabolic diseases. This review explores the molecular characteristics of CLA, its metabolic pathways, and its inconsistent effects on lipid metabolism, adipogenesis, energy expenditure, and inflammation. Preclinical and clinical studies suggest that CLA may promote fat oxidation and modulate adipocyte function; however, inconsistent findings highlight dose‐dependent outcomes and individual variability in response. The dual nature of CLA, showing both beneficial and adverse effects, raises questions about its long‐term safety and efficacy. This review critically examines CLA's molecular role in obesity and metabolic regulation, providing insights into its therapeutic promise and limitations. Future research should focus on personalized approaches to CLA supplementation, considering genetic and lifestyle factors for tailored nutritional guidance.

Conjugated linoleic acid (CLA) modulates lipid metabolism, adipogenesis, energy expenditure, and inflammation, showing anti‐obesity effects in animal models. However, human studies reveal inconsistent outcomes due to dosage, isomer type, and individual variability. Personalized supplementation strategies are essential to maximize CLA's benefits while minimizing metabolic risks.